Preliminary results from a FIH, open-label phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab

被引：0
|
作者：
Perets, Ruth
Meshner, Shiri
Tirosh, Osnat
Eshar, Shiri
Metz-Breiner, Alona
Ben-Shabat, Sheerli Kruger
Ben-Yehuda, Hila
Haber, Elran
Cohen-Asis, Meital
Maurice-Dror, Corinne
Ringel, Yehuda
Holland, Roy
Shirman, Yelena
Kutiel, Talia Shentzer
机构：
[1] Technion Israel Inst Technol, Rambam Hlth Care Campus, Haifa, Israel
[2] Biomica, Rehovot, Israel
[3] BC Canc Agcy, Vancouver, BC, Canada
[4] Rambam Med Ctr, Haifa, Israel
[5] Rambam Hlth Care Campus, Div Oncol, Haifa, Israel
[6] Rambam Med Ctr, Haifa, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8631
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Interim results from a phase 2, open-label study evaluating an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in wolfram syndrome (HELIOS)
    Urano, F.
    Hurst, S.
    Marshall, B.
    Erpelding, N.
    Cottrell, K.
    Leinders, M.
    Mehta, L.
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 50 - 50
  • [42] Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study
    Pietrantonio, F.
    Ho, G. F.
    Su, Y-L.
    Chen, E. X.
    Yuan, Y.
    Voon, P-J.
    Liang, X.
    Jonker, D.
    Longo Munoz, F.
    Hecht, J. R.
    Chandana, S.
    Arnold, D.
    Bhattacharya, R.
    Curtin, J. C.
    Maul, S.
    Iwasawa, R.
    Chowdhury, S.
    Schnepp, R. W.
    Baig, M.
    Hong, Y. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S434 - S434
  • [43] Histological Analysis of the Effect of ATX-101 (Deoxycholic Acid Injection) on Subcutaneous Fat: Results From a Phase 1 Open-Label Study
    Walker, Patricia S.
    Lee, Daniel R.
    Toth, Bryant A.
    Bowen, Beta
    DERMATOLOGIC SURGERY, 2020, 46 (01) : 70 - 77
  • [44] FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.
    Li, Qiao
    Cheng, Ying
    Tong, Zhongsheng
    Liu, Yunjiang
    Wang, Xian
    Yan, Min
    Chang, Jianhua
    Wang, Shusen
    Du, Caiwen
    Li, Liang
    Wu, Chunjiao
    Wang, Mingxia
    Wang, Zhuo
    Wu, Zhuli
    Jin, Yongli
    Zhang, Yongjiao
    Hui, Ai-Min
    Wang, Xingli
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Final results from a phase 1/2, 48-month, open-label extension study of givosiran in patients with acute intermittent porphyria
    Sardh, Eliane
    Balwani, Manisha
    Rees, David
    Anderson, Karl
    Jia, Gang
    Sweetser, Marianne T.
    Wang, Bruce
    JOURNAL OF HEPATOLOGY, 2023, 78 : S92 - S93
  • [46] Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
    Felip, Enriqueta
    de Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Thomas
    Liu, Geoffrey
    Lolkema, Martijn P.
    Selvaggi, Giovanni
    Giannone, Vanessa
    Cazorla, Pilar
    Baum, Jason
    Balbin, O. Alejandro
    Wang, Luojun
    Lau, Yvonne Y.
    Scott, Jeffrey W.
    Tan, Daniel Shao-Weng
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : 392 - 403
  • [47] Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
    Hellmann, Matthew D.
    Rizvi, Naiyer A.
    Goldman, Jonathan W.
    Gettinger, Scott N.
    Borghaei, Hossein
    Brahmer, Julie R.
    Ready, Neal E.
    Gerber, David E.
    Chow, Laura Q.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott A.
    Geese, William J.
    Agrawal, Shruti
    Young, Tina C.
    Li, Xuemei
    Antonia, Scott J.
    LANCET ONCOLOGY, 2017, 18 (01): : 31 - 41
  • [48] A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: Preliminary results of a phase IB study.
    Voortman, J
    Smit, EF
    Kuenen, BC
    Pinedo, HM
    van Groeningen, C
    van den Eertwegh, AJ
    Brouwer, D
    van de Velde, H
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 160S - 160S
  • [49] A phase 1 B, open-label, dose-escalation study of bortezomib (Btz) in combination with gemcitabine (G) and cisplatin (C) in the first-line treatment of patients with advanced solid tumors: preliminary results
    Voortman, J.
    Smit, E. F.
    Kuenen, B. C.
    van de Velde, H.
    Giaccone, G.
    EJC SUPPLEMENTS, 2005, 3 (02): : 425 - 425
  • [50] Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma
    McKean, Meredith
    Aggen, David Henry
    Lakhani, Nehal J.
    Bashir, Babar
    Luke, Jason J.
    Hoffman-Censits, Jean H.
    Alhalabi, Omar
    Bowman, Isaac Alex
    Guancial, Elizabeth A.
    Tan, Alan
    Lingaraj, Trupti
    Timothy, Marissa
    Kacena, Katherine
    Malek, Karim S.
    Santillana, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345